NeuroPace Inc (NAS:NPCE)
$ 7.53 -0.07 (-0.92%) Market Cap: 216.62 Mil Enterprise Value: 232.78 Mil PE Ratio: 0 PB Ratio: 15.23 GF Score: 55/100

Neuropace Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2022 / 01:30PM GMT
Release Date Price: $5.86 (+14.90%)
Rhea McFarlane
RBC Dominion Securities, Inc. - Investment Advisor & Financial Planner

From the company is Mike Favet, Chief Executive Officer. And we're sorry, Rebecca couldn't be here today, the Chief Financial Officer.

Just by way of background, NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available brain responsive platform that delivers personalized real-time treatment at the seizure source.

Mike, thank you so much for being here today. And again, the floor is yours.

Mike Favet
NeuroPace, Inc. - CEO

Rhea, thank you. Is the microphone working? It sounds like it? Thank you for the opportunity to be here. I was sharing earlier that this is my first in-person investor conference in over two years. So very glad to be back to doing some of these in person, and thanks for the introduction.

So standard

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot